We Just Had An Epiphany

Tag: hub-insiders

Oracle AI data-center illustration showing surging cloud demand, a $664 billion backlog, heavy capital spending and negative free cash flow.

Oracle Stock (ORCL): Can a $664 Billion Backlog Outrun the AI Capex Bill?

Oracle’s cloud-infrastructure revenue surged 121% as remaining performance obligations reached $664 billion. With Larry Ellison still owning roughly 40%, institutions controlling most of the float and valuation sharply compressed, ORCL looks compelling—but heavy debt, negative free cash flow and an enormous AI buildout make execution everything.

Read entire article

Tags: AI chips, Artificial Intelligence, buy or sell ORCL, capital expenditures, cloud computing, Cloud Infrastructure, cloud stocks, data centers, Earnings Summary, featured-epiphany, founder-led companies, free cash flow, FUNstock Index, FunStock Method, GARP investing, growth at a reasonable price, growth stocks, hub-epiphany, hub-insiders, hyperscalers, insider ownership, institutional ownership, Larry Ellison, OCI, OpenAI, Oracle, Oracle Cloud Infrastructure, Oracle earnings, Oracle RPO, Oracle stock, ORCL, ORCL stock, Project Jupiter, remaining performance obligations, risks buying ORCL, Stargate, stock analysis, Tech Stocks, technology stocks, Tencent, Valuation, value investing, why buy ORCL
A futuristic biotech laboratory filled with glowing strands of messenger RNA weaving through multiple medical breakthroughs. At the center stands a luminous DNA-style platform branching into colorful pathways labeled

🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued

Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.

Read entire article

Tags: AI Drug Discovery, Biotech Stocks, BiotechInvesting, Biotechnology, BiotechStocks, buy or sell MRNA, CancerVaccines, CAR-T, featured-epiphany, Fidelity, FUNanc1al, FUNanc1al Investing, GrowthInvesting, hub-epiphany, hub-insiders, In Vivo CAR-T, InsiderBuying, Intismeran, Investing, Moderna, Moderna Stock, MRNA, NASDAQ, Oncology, PDUFA, Personalized Cancer Vaccine, risks buying MRNA, ShortSqueeze, Stéphane Bancel, StephaneBancel, Stock Analysis, Vaccine Stocks, Value Investing, ValueInvesting, why buy MRNA